{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:49:50Z","timestamp":1790812190314,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007072","name":"Onyx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1111\/bjh.14549","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:58:37Z","timestamp":1487329117000},"page":"404-413","source":"Crossref","is-referenced-by-count":63,"title":["Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study"],"prefix":"10.1111","volume":"177","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens; Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic; Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"St Istv\u00e1n and St Laszlo Hospital; 3rd Dept. of Internal Medicine; Semmelweis University; Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine; Charles University in Prague; Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia; Hospital Germans Trias i Pujol; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"University Hospital Ostrava and Faculty of Medicine; University of Ostrava; Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University; Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi G.","family":"Mihaylov","sequence":"additional","affiliation":[{"name":"Queen Joanna University Hospital; Sofia Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesselina","family":"Goranova-Marinova","sequence":"additional","affiliation":[{"name":"Haematology Clinic University Multiprofile Hospital for Active Treatment; Plovdiv Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-5826","authenticated-orcid":false,"given":"P\u00e9ter","family":"Rajnics","sequence":"additional","affiliation":[{"name":"Department of Haematology; M\u00f3r Kaposi Teaching Hospital; Kaposv\u00e1r Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Suvorov","sequence":"additional","affiliation":[{"name":"Haematological Department; First Republican Clinical Hospital of Udmurtia; Izhevsk Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College; New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center; Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra; CIMA; IDISNA; Pamplona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Wilhelminen Cancer Research Institute; Wilhelminenspital; Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"University of Torino; Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Obreja","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, Inc. an Amgen subsidiary; South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, Inc. an Amgen subsidiary; South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University of Nantes; Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"10.1111\/bjh.14549-BIB0001|bjh14549-cit-0001","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1111\/bjh.14549-BIB0002|bjh14549-cit-0002","first-page":"8","article-title":"Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma","volume":"17","author":"Azarm","year":"2012","journal-title":"Journal of Research in Medicine Sciences"},{"key":"10.1111\/bjh.14549-BIB0003|bjh14549-cit-0003","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/bjh.14549-BIB0004|bjh14549-cit-0004","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/CAD.0000000000000285","article-title":"Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Castelli","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"10.1111\/bjh.14549-BIB0005|bjh14549-cit-0005","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/10428194.2010.530361","article-title":"Treatment of multiple myeloma in the elderly: realities and hopes","volume":"52","author":"Rubia","year":"2011","journal-title":"Leukemia & Lymphoma"},{"key":"10.1111\/bjh.14549-BIB0006|bjh14549-cit-0006","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1200\/JCO.2002.05.088","article-title":"Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer","volume":"20","author":"Du","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.14549-BIB0007|bjh14549-cit-0007","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1111\/bjh.14549-BIB0008|bjh14549-cit-0008","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.3324\/haematol.2014.110395","article-title":"Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma","volume":"99","author":"Dytfeld","year":"2014","journal-title":"Haematologica"},{"key":"10.1111\/bjh.14549-BIB0009|bjh14549-cit-0009","first-page":"87","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1111\/bjh.14549-BIB0010|bjh14549-cit-0010","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75\u00a0years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.14549-BIB0011|bjh14549-cit-0011","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjh.14549-BIB0012|bjh14549-cit-0012","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2165\/00002512-200320100-00003","article-title":"Pharmacological factors influencing anticancer drug selection in the elderly","volume":"20","author":"John","year":"2003","journal-title":"Drugs and Aging"},{"key":"10.1111\/bjh.14549-BIB0013|bjh14549-cit-0013","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4140\/TCP.n.2014.434","article-title":"Multiple myeloma treatment and management in the elderly","volume":"29","author":"Johnson","year":"2014","journal-title":"The Consultant Pharmacist"},{"key":"10.1111\/bjh.14549-BIB0014|bjh14549-cit-0014","first-page":"5","article-title":"Relapsed or relapsed\/refractory multiple myeloma","volume":"4","author":"Kurtin","year":"2013","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"key":"10.1111\/bjh.14549-BIB0015|bjh14549-cit-0015","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study","volume":"108","author":"Mateos","year":"2006","journal-title":"Blood"},{"key":"10.1111\/bjh.14549-BIB0016|bjh14549-cit-0016","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/bjh.14549-BIB0017|bjh14549-cit-0017","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.1111\/bjh.14549-BIB0018|bjh14549-cit-0018","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2146\/ajhp130281","article-title":"Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma","volume":"72","author":"McBride","year":"2015","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1111\/bjh.14549-BIB0019|bjh14549-cit-0019","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.2165\/11209010-000000000-00000","article-title":"Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"key":"10.1111\/bjh.14549-BIB0020|bjh14549-cit-0020","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3109\/10428191003695660","article-title":"Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide","volume":"51","author":"Mele","year":"2010","journal-title":"Leukemia & Lymphoma"},{"key":"10.1111\/bjh.14549-BIB0021|bjh14549-cit-0021","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1111\/bjh.14549-BIB0022|bjh14549-cit-0022","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1182\/blood-2015-02-626168","article-title":"Phase 1\/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65\u00a0years with newly diagnosed multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"10.1111\/bjh.14549-BIB0023|bjh14549-cit-0023","first-page":"190","article-title":"Novel treatment paradigm for elderly patients with multiple myeloma","volume":"1","author":"Palumbo","year":"2011","journal-title":"American Journal of Blood Research"},{"key":"10.1111\/bjh.14549-BIB0024|bjh14549-cit-0024","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1111\/bjh.14549-BIB0025|bjh14549-cit-0025","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/cncr.27820","article-title":"Bortezomib, melphalan, and prednisone in elderly patients with relapsed\/refractory multiple myeloma: a multicenter, open label phase 1\/2 study","volume":"119","author":"Petrucci","year":"2013","journal-title":"Cancer"},{"key":"10.1111\/bjh.14549-BIB0026|bjh14549-cit-0026","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"10.1111\/bjh.14549-BIB0027|bjh14549-cit-0027","first-page":"18","article-title":"Greater risks of chemotherapy toxicity in elderly patients with cancer","volume":"1","author":"Repetto","year":"2003","journal-title":"Journal of Supportive Oncology"},{"key":"10.1111\/bjh.14549-BIB0028|bjh14549-cit-0028","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06585.x","article-title":"Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma","volume":"137","author":"Richardson","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.14549-BIB0029|bjh14549-cit-0029","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.3324\/haematol.2014.110890","article-title":"Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial","volume":"100","author":"Rodon","year":"2015","journal-title":"Haematologica"},{"key":"10.1111\/bjh.14549-BIB0030|bjh14549-cit-0030","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjh.14549-BIB0031|bjh14549-cit-0031","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.14549-BIB0032|bjh14549-cit-0032","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B","article-title":"Aging and pharmacology","volume":"80","author":"Vestal","year":"1997","journal-title":"Cancer"},{"key":"10.1111\/bjh.14549-BIB0033|bjh14549-cit-0033","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1200\/JCO.2001.19.4.1147","article-title":"Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base","volume":"19","author":"Yancik","year":"2001","journal-title":"Journal of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.14549\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T08:21:40Z","timestamp":1625386900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.14549","archive":["Portico"],"relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}